We are live on ! Find out more
Boxer Capital

Boxer Capital Portfolio holdings

AUM $2.04B Turnover 20.83%
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+19.25%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.1%
10 Year Est. Return
–
AUM
$421M
AUM Growth
-$37.1M
Cap. Flow
-$59.9M
Cap. Flow %
-14.25%
Top 10 Hldgs %
82.19%
Holding
34
New
3
Increased
4
Reduced
9
Closed
7
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 94.42%
2 Miscellaneous 5.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
AVXS
1
DELISTED
AveXis
AVXS
$65.7M 15.63%
800,000
-228,763
-22% -$17.2M
2016 Q1
5 quarters
CLVS
2
DELISTED
Clovis Oncology
CLVS
$46.8M 11.13%
500,000
-500,000
-50% -$30.6M
2016 Q2
4 quarters
ESPR icon
3
DELISTED
Esperion Therapeutics
ESPR
$46.3M 11.01%
1,000,000
-275,000
-22% -$10.1M
2017 Q1
1 quarter
MDCO
4
DELISTED
Medicines Co
MDCO
$46.2M 10.98%
1,215,000
– –
2016 Q3
3 quarters
MGNX icon
5
MacroGenics
MGNX
$127M
$37M 8.81%
+2,115,000
New +$40.3M
2017 Q2
0 quarters
PTCT icon
6
PTC Therapeutics
PTCT
$4.87B
$31.2M 7.41%
1,700,000
+200,000
+13% +$2.69M
2017 Q1
1 quarter
ONC icon
7
BeOne Medicines
ONC
$45.7B
$27M 6.42%
600,000
-250,000
-29% -$9.9M
2016 Q1
5 quarters
MDCO
8
CALL
DELISTED
Medicines Co
MDCO
$20.2M 4.8%
530,600
-153,100
-22% -$6.82M
2016 Q3
3 quarters
BPMC icon
9
DELISTED
Blueprint Medicines
BPMC
$12.7M 3.01%
250,000
-520,159
-68% -$22.1M
2015 Q4
6 quarters
INCY icon
10
Incyte
INCY
$23.6B
$12.6M 2.99%
100,000
– –
2016 Q1
5 quarters
GTHX icon
11
DELISTED
G1 Therapeutics
GTHX
$11M 2.61%
+629,179
New +$11M
2017 Q2
0 quarters
PBYI icon
12
Puma Biotechnology
PBYI
$368M
$8.74M 2.08%
100,000
– –
2017 Q1
1 quarter
LJPC
13
DELISTED
La Jolla Pharmaceutical
LJPC
$7.96M 1.89%
267,500
+100,100
+60% +$2.87M
2017 Q1
1 quarter
NGNE icon
14
Neurogene
NGNE
$475M
$7.39M 1.76%
26,250
-17,638
-40% -$5.05M
2015 Q4
6 quarters
SBBP
15
DELISTED
Strongbridge Biopharma
SBBP
$6.72M 1.6%
940,000
– –
2016 Q4
2 quarters
SGEN
16
DELISTED
Seagen
SGEN
$6.47M 1.54%
125,000
+25,000
+25% +$1.59M
2015 Q4
6 quarters
KURA icon
17
Kura Oncology
KURA
$675M
$4.96M 1.18%
533,251
– –
2015 Q4
6 quarters
MRTX
18
DELISTED
Mirati Therapeutics
MRTX
$3.79M 0.9%
1,037,994
– –
2015 Q4
6 quarters
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$822M
$3.27M 0.78%
234,220
– –
2016 Q1
5 quarters
VXX icon
20
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 2019
VXX
$3.19M 0.76%
+62,500
New +$3.61M
2017 Q2
0 quarters
VIRX icon
21
DELISTED
Viracta Therapeutics
VIRX
$2.77M 0.66%
29,286
+14,286
+95% +$1.64M
2016 Q4
2 quarters
BLPH
22
DELISTED
Bellerophon Therapeutics
BLPH
$2.49M 0.59%
123,810
– –
2016 Q4
2 quarters
CBAY icon
23
DELISTED
Cymabay Therapeutics
CBAY
$2.45M 0.58%
425,000
-352,202
-45% -$1.5M
2017 Q1
1 quarter
NBRV
24
DELISTED
Nabriva Therapeutics
NBRV
$1.85M 0.44%
707
– –
2015 Q4
6 quarters
EIGR
25
DELISTED
Eiger BioPharmaceuticals
EIGR
$1.09M 0.26%
4,611
– –
2015 Q4
6 quarters

Similar funds

Boxer Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Boxer Capital held 34 positions worth $421M, down 8.1% from $458M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Boxer Capital withdrew a net $59.9M in Q2 2017, closing 7 positions and reducing 9 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, Boxer Capital opened a new position in MacroGenics worth $37M.

  • Boxer Capital's largest Q2 2017 buy was MacroGenics: 2,115,000 shares worth $37M.
  • Boxer Capital added most to La Jolla Pharmaceutical in Q2 2017, an estimated $2.87M increase.
  • Boxer Capital's biggest Q2 2017 reduction was Clovis Oncology, cutting an estimated $30.6M.
  • Boxer Capital fully exited Alnylam Pharmaceuticals in Q2 2017, selling an estimated $12.8M.
  • Boxer Capital's ten largest holdings make up 82% of its $421M portfolio in Q2 2017.
  • Boxer Capital opened 3 new positions and closed 7 in Q2 2017.
  • Boxer Capital's portfolio value fell 8.1% quarter-over-quarter to $421M.

Based on Boxer Capital's 13F filing for Q2 2017, filed 14 Aug 2017.